4565 Nxera Pharma
- 1232
- +27+2.24%
Nxera Pharma News
Nxera Pharma: Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ in Japan
Nxera Pharma: Notice of a new partnership with Shionogi Pharmaceutical regarding the insomnia remedy “Kubivic tablets” targeting the Japanese market
Nxera Pharma: Articles of Incorporation 2024/04/01
Nxera Pharma: Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Nxera Pharma: We have received a USD 35 million milestone from Neurocline due to the positive results of the Phase 2 clinical trial of the candidate NBI-1117568 for schizophrenia
Nxera Pharma: Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Nxera Pharma: Good results in phase 2 clinical trials of schizophrenia drug candidate NBI-1117568, which is a partnership program with Neurocline
Nxera Pharma: Consolidated financial results (IFRS) for the six-month period ending on June 30, 2024.
Nxera Pharma: Business highlights and consolidated performance for the second quarter and first half of 2024 for Nxera Pharma.
Nxera Pharma: Due to the collaboration targeting neurological disorders achieving the first milestone of research and development, Nxera Pharma received 10 million US dollars from Abbvie.
Nxera Pharma: Received a milestone payment of 10 million US dollars in a drug development partnership with Abbvie targeting neurological diseases.
Sosei Group: Nxera Pharma Receives $4.6 Million Milestone Payment from Centesa Pharmaceuticals
Sosei Group: Centessa received a USD 4.6 million milestone
Sosei Group: Notice of commencement of phase 1 clinical trial of NBI-1117567 targeting healthy adults by Neurocline, our partner
Sosei Group: Nxera Pharma's business highlights and consolidated results for the first quarter of 2024
Sosei Group: Consolidated financial results (IFRS) for the three months ended March 31, 2024
Nexera Pharma: Notice regarding issuance of new shares based on the RSU plan, determination of PMT amounts, and other issuance of new shares based on the previous year's RSU
Sosei Group: Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
Sosei Group: Long-term toxicity testing of the oral M4 receptor agonist NBI-1117568, which is a partnership program with Neurocline, was successful
Sosei Group: Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ in South Korea
Analysis
Price Target
No Data
No Data